Lumigan is a medication used to treat high pressure inside the eye including glaucoma and is owned by Abbvie. It contains the active ingredient Bimatoprost. It was first authorized for medical use in 2010. The global opthamology drug market was valued US$ 33 billion in 2022. There were 12 drug patents protecting lumigan in United States, but as of now none of those patents have expired.
lumigan (Bimatoprost) currently had patent protection until June 13, 2027. This means lumigan will be available in the market after June 13, 2027, unless a Paragraph IV certification was filed challenging the patents before expiration.
Lumigan is approved to treat open-angle glaucoma and ocular hypertension in adults. The active ingredient in Lumigan, Bimatoprost, is a prostaglandin analog that works by increasing the outflow of aqueous humor through the trabecular meshwork and uveoscleral routes. This lowers intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Lumigan is administered as an ophthalmic solution/eye drops to directly target the eye for reducing elevated intraocular pressure.
Lumigan currently holds 12 patents covering various aspects, including the active ingredient and formulation. The main drug substance patent will expire in June 2027, marking a significant milestone for the medication. With patents lasting over 4 more years, patent expiration will prevent lumigan generic until 2027. Below is a list of the recent lumigan patent expirations -